In which case it doesnt matter whether we increase dystrophin or...

In which case it doesnt matter whether we increase dystrophin or not, we still achieve better results, in a mouse study, in combo with exon skipping.

I agree it does seem strange that results were "INSUFFICIENTLY SENSITIVE" ....what does that mean, and how could they not foresee such an outcome.

To continue down the rabbit hole... Sarepta can kick the can down the road with the fda (remember fda can now relinquish approvals) until our tox study is complete, or well underway to then swap over to ATL1102 when we have rights to monetise our drug. If we were to give advocates a sniff of another option (unapproved ANP) sarepta may lose valuable revenue, on marketing hold, waiting for us to jump the monkey hurdle. Because you wouldnt get behind a drug if there was something better just around the corner.